| Description | NMS-P118 is a potent, selective and orally available Inhibitor of PARP-1 for cancer therapy. |
| In vitro | NMS-P118 proved to be a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in vivo both as a single agent and in combination with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively. Cocrystal structures of 20by with both PARP-1 and PARP-2 catalytic domain proteins allowed rationalization of the observed selectivity. |
| Target activity | PARP2:1390 nM (Kd), PARP1:9 nM (Kd) |
| molecular weight | 395.42 |
| Molecular formula | C20H24F3N3O2 |
| CAS | 1262417-51-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 16 mg/mL (40.46 mM), Sonication and heating are recommended. |
| References | 1. Papeo G, et al. Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. J Med Chem. 2015 Sep 10;58(17):6875-98. |